Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $62.78.

HALO has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday. Benchmark reiterated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th.

Halozyme Therapeutics Trading Up 1.0 %

HALO traded up $0.60 during trading on Tuesday, reaching $60.75. 666,137 shares of the stock traded hands, compared to its average volume of 1,301,696. The stock's 50-day moving average is $55.44 and its 200 day moving average is $54.78. Halozyme Therapeutics has a 12 month low of $37.73 and a 12 month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The stock has a market capitalization of $7.48 billion, a PE ratio of 17.75, a P/E/G ratio of 0.42 and a beta of 1.25.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock worth $1,754,451 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Halozyme Therapeutics by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company's stock worth $261,000 after purchasing an additional 782 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Halozyme Therapeutics by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company's stock valued at $849,000 after acquiring an additional 995 shares during the period. Nisa Investment Advisors LLC increased its stake in Halozyme Therapeutics by 32.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company's stock worth $315,000 after buying an additional 1,358 shares in the last quarter. New York State Teachers Retirement System boosted its position in Halozyme Therapeutics by 12.8% during the third quarter. New York State Teachers Retirement System now owns 127,327 shares of the biopharmaceutical company's stock worth $7,288,000 after acquiring an additional 14,489 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 1,028 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.